AngioDynamics (ANGO)
(Delayed Data from NSDQ)
$7.48 USD
+0.35 (4.91%)
Updated Jul 23, 2024 04:00 PM ET
After-Market: $7.47 -0.01 (-0.13%) 7:58 PM ET
3-Hold of 5 3
B Value A Growth A Momentum A VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ANGO 7.48 +0.35(4.91%)
Will ANGO be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for ANGO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ANGO
AngioDynamics (ANGO) Q4 Earnings Top Estimates, Gross Margin Down
AngioDynamics (ANGO) Reports Q4 Loss, Tops Revenue Estimates
ANGO: What are Zacks experts saying now?
Zacks Private Portfolio Services
AngioDynamics' (ANGO) AlphaVac System Gets CE Mark Approval
AngioDynamics (ANGO) Q3 Earnings and Revenues Miss Estimates
AngioDynamics' (ANGO) AlphaVac Gets FDA Nod for PE Treatment
Other News for ANGO
Reaffirmed Buy Rating on AngioDynamics: A Strategic Assessment of Growth and Valuation Prospects
Analysts Offer Insights on Healthcare Companies: Teladoc (TDOC), Argenx Se (ARGX) and AngioDynamics (ANGO)
AngioDynamics price target lowered by $5 at Canaccord, here's why
AngioDynamics: Lumpy Progress Is Still Progress
AngioDynamics Inc (ANGO) Q4 2024 Earnings Call Transcript Highlights: Strong MedTech Growth ...